Prime Medicine (PRME) Accumulated Expenses (2021 - 2026)

Prime Medicine's Accumulated Expenses history runs 6 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• Quarterly Accumulated Expenses fell 11.89% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (down 11.89% YoY) and the FY2025 annual result came in at $12.6 million, down 20.77% from the prior year.
• Accumulated Expenses was $8.1 million for Q1 2026 at Prime Medicine, down from $12.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $18.7 million in Q3 2024 and bottomed at $300000.0 in Q2 2023.
• A 5-year average of $10.6 million and a median of $10.9 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 71.26% — and 2024, when it jumped 3531.67%.
• Prime Medicine's Accumulated Expenses stood at $10.7 million in 2022, then jumped by 32.02% to $14.1 million in 2023, then advanced by 12.71% to $15.9 million in 2024, then retreated by 20.77% to $12.6 million in 2025, then sank by 35.73% to $8.1 million in 2026.
• Business Quant data shows PRME's Accumulated Expenses at $8.1 million in Q1 2026, $12.6 million in Q4 2025, and $11.0 million in Q3 2025.